Tiliroside From <i>Pavonia malacophylla</i> (Link & Otto) Garcke as an Anti‐SARS‐CoV‐2 Cell Entry Agent
of 18.5 µM. Molecular docking revealed strong binding of tiliroside to the Spike RBD, involving Lys417, Gly496, Tyr495, Tyr453, and Tyr505, with a predicted higher affinity than that of remdesivir and nafamostat. These results provide the first in vitro evidence that tiliroside may be a SARS-CoV-2 entry inhibitor, highlighting O-glycosylated flavonoids as antiviral scaffolds.
Authors
- Mariana Freire Campos (ORCID: https://orcid.org/0000-0002-3032-3148)
- Gilda Guimarães Leitão (ORCID: https://orcid.org/0000-0003-2577-3993)
- María de Fátima Vanderlei de Souza (ORCID: https://orcid.org/0000-0002-9936-7130)
- Diégina Araújo Fernandes (ORCID: https://orcid.org/0000-0001-6120-761X)
- Renata Priscila Barros de Menezes
- Diego Allonso (ORCID: https://orcid.org/0000-0002-1410-480X)
- Suzana Guimarães Leitão (ORCID: https://orcid.org/0000-0001-7445-074X)
- Marcus Tullius Scotti (ORCID: https://orcid.org/0000-0003-4863-8057)
- Janderson Barbosa Leite de Albuquerque
Institutions
- Universidade Federal do Rio de Janeiro (BR)
- Universidade Federal da Paraíba (BR)
Publication Details
- Journal
- Chemistry & Biodiversity
- Published
- 2026-05-01
- DOI
- https://doi.org/10.1002/cbdv.202502999
- Primary Topic
- Herbal Medicine and Trade Cooperation
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro